Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 2;20(19):4886.
doi: 10.3390/ijms20194886.

PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review

Christophe Van de Wiele  1   2 , Mike Sathekge  3 , Bart de Spiegeleer  4 , Pieter Jan de Jonghe  5 , Laurence Beels  6 , Alex Maes  7   8
Affiliations

PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review

Christophe Van de Wiele et al. Int J Mol Sci. .

Abstract

Despite its name, prostate-specific membrane antigen (PSMA) has been shown using immunohistochemistry (IHC) to also be over-expressed in the tumor neovasculature of a wide variety of solid tumors other than prostate carcinoma. Accordingly, positron-emitting radiolabeled small molecules targeting PSMA, initially developed for positron emission tomography in prostate carcinomas, are currently being explored for their staging and restaging potential as an alternative imaging modality in other solid tumor types where 18-F-fluorodeoxyglucose (FDG)-PET imaging has low diagnostic accuracy. In this paper, the currently available literature in this field is reviewed. Preliminary, mainly retrospective studies are encouraging, with evidence of improved diagnostic sensitivity and specificity in clear cell renal carcinoma, glioma, and hepatocellular carcinoma, leading to a change in patient management in several patients. However, the results published thus far warrant confirmation by larger prospective studies additionally assessing the longitudinal impact on patient outcomes.

Keywords: PSMA; non prostate carcinoma; positron emission tomography (PET).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Evans J., Malhotra M., Cryan J., O’Driscoll C. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br. J. Pharmacol. 2016;173:3041–3079. doi: 10.1111/bph.13576. - DOI - PMC - PubMed
    1. Horoszewicz J., Kawinski E., Murphy G. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1986;7:927–935. - PubMed
    1. Israeli R., Powell C., Fair W., Heston W. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227–230. - PubMed
    1. Chang S., Gaudin P., Reuter V., Heston W. Prostate-specific membrane antigen: Present and future applications. Urology. 2000;55:622–629. doi: 10.1016/S0090-4295(99)00600-7. - DOI - PubMed
    1. Virgolini I., Decristoforo C., Haug A., Fanti S., Uprimny C. Current status of theranostics in prostate cancer. EJNMMI. 2018;45:471–495. doi: 10.1007/s00259-017-3882-2. - DOI - PMC - PubMed

Publication types

LinkOut - more resources